NCT01621750已完成1 期
An Open Label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Single-dose, Crossover Oral Bioequivalence Study of Clopidogrel Bisulfate 300 mg Tablets of Dr. Reddy's Laboratories Ltd., India and Plavix® (Clopidogrel Bisulfate) 300 mg Tablets Under Fasting Conditions
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 68
- 试验地点
- 1
- 主要终点
- Area under curve(AUC)
研究概览
简要总结
To compare the bioavailability and characterize the pharmacokinetic profile of the Sponsor's formulation (Clopidogrel Bisulfate 300 mg Tablets) with respect to the reference formulation (Plavix® 300 mg tablets) in healthy, adult, human, male subjects under fasting conditions and to assess the bioequivalence.
详细描述
An open label, balanced, randomized, two treatment, two sequence, two period, single-dose, crossover oral bioequivalence study of Clopidogrel Bisulfate 300 mg Tablets of Dr. Reddy's Laboratories Ltd., India and Plavix® (Clopidogrel Bisulfate) 300 mg Tablets of Bristol-Myers Squibb/Sanofi pharmaceuticals partnership Bridgewater, NJ 0880750086441, USA, in healthy, adult, human male subjects under fasting conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy adult human male volunteers between 18 and 55 years of age (both inclusive) living in and around Ahmedabad city of western part of India.
- •Having a Body Mass Index (BMI) between 18.5 and 24.9 (both inclusive), calculated as weight in kg/height in m
- •Not having any significant diseases or clinically significant abnormal findings during screening, medical history, clinical examination, laboratory evaluations, 12-lead ECG and X-ray chest (postero-anterior view) recordings.
- •Able to understand and comply with the study procedures, in the opinion of the Principal investigator.
- •Able to give voluntary written consent for participation in the trial.
排除标准
- •Known hypersensitivity or idiosyncratic reaction to Clopidogrel or any related drug.
- •History or presence of any disease or condition which might compromise the haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal or any other body system.
- •Ingestion of any medication at any time in 14 days prior to the dosing of Period-I. In any such case subject selection was at the discretion of the Principal Investigator.
- •Any history or presence of asthma (including aspirin induced asthma) or nasal polyp or NSAID induced urticaria.
- •A recent history of alcoholism (less than 2 years) or daily consumption of moderate (180 mL / day) alcohol use or consumption of alcohol within 48 hours prior to receiving the study medicine.
- •The presence of clinically significant abnormal laboratory values including APTT and PT during screening.
- •Consumption of grapefruit and/or grapefruit products within 48hrs prior to dosing.
- •Use of any recreational drugs or history of drug addiction or testing positive in pre-study drug scans.
- •History of psychiatric disorders.
- •A history of difficulty in donating blood.
- •Donation of blood (1 unit or 350 mL) within 90 days prior to receiving the first dose of IP.
- •Note: In case the blood loss was less than or equal to 200 mL; subject was enrolled 60 days after blood donation.
- •Smokers, who smoked more than 10 cigarettes / day or inability to abstain from smoking during the study.
- •A positive hepatitis screen including hepatitis B surface antigen, HCV antibodies.
- •A positive test result for HIV antibody and/or syphilis.
- •The receipt of an investigational product or participation in a drug research study within a period of 90 days prior to the first dose of study medication. Elimination half-life of the study drug was taken into consideration for inclusion of the subject in the study.
- •Note: If subject had participated in a study in which blood loss was less than or equal to 200 mL, subject was dosed 60 days after the last sample of previous study.
- •An unusual diet, for whatever reason (e.g. low-sodium), for four weeks prior to receiving the study medication and throughout the subjects' participation in the study. In any such case subject selection was at the discretion of the Principal Investigator.
- •Any history of peptic ulcer disease, which include gastric & duodenal ulcer or any other bleeding disorders.
研究组 & 干预措施
Plavix
Active Comparator
Clopidogrel Tablet 300 mg
干预措施: Clopidogrel (Drug)
Clopidogrel
Experimental
Clopidogrel tablets 300 mg of Dr. Reddy's Laboratories Limited
干预措施: Clopidogrel (Drug)
结局指标
主要结局
Area under curve(AUC)
时间窗: at pre-dose 0.25, 0.50, 0.75, 1.00, 1.25, 1.50, 1.75, 2.00, 2.25, 2.50, 3.00, 4.00, 6.00, 8.00, 12.00, 16.00, 20.00, 24.00, 36.00 and 48.00 hours post dose
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Bioequivalence Study of Clopidogrel Tablets 300 mg Under Fed ConditionsHealthyNCT01621763Dr. Reddy's Laboratories Limited68
已完成
1 期
Bioequivalence Study of Two Products of Apixaban 5mg Tablets in Healthy, Adult, Human SubjectsAntithrombic DrugNCT06043297Humanis Saglık Anonim Sirketi30
已完成
1 期
Bioequivalence Study of Mycophenolate Mofetil 500 mg Tablets of Dr.Reddy's Laboratories Limited Under Non-Fasting ConditionsFEDNCT01283867Dr. Reddy's Laboratories Limited92
已完成
1 期
Bioequivalence Study of Mycophenolate Mofetil 500 mg Tablets of Dr.Reddy's Laboratories Limited Under Fasting ConditionsFastingNCT01283841Dr. Reddy's Laboratories Limited48
已完成
1 期
Bioequivalence Study of Two Products of Tenofovir Alafenamide 25 mg Film Tablet in Healthy, Adult, Human SubjectsChronic Hepatitis B in Adults and Paediatric PatientsNCT06592300Humanis Saglık Anonim Sirketi42